Literature DB >> 9972860

Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan.

J E Rose1, E C Westman, F M Behm, M P Johnson, J S Goldberg.   

Abstract

The present study was conducted to investigate the role of peripheral nicotinic receptors in mediating the rewarding effects of cigarette smoking. Twelve cigarette smokers rated cigarettes after intravenous infusion of the short-acting peripheral nicotinic receptor antagonist trimethaphan and after placebo (saline) infusions. Subjects were blinded to the infusion and cigarette conditions. Cigarette conditions included subjects' usual brand of cigarette, denicotinized tobacco cigarettes, and nicotine-injected cigarettes that had a tar delivery equal to that of the denicotinized cigarettes but with an enhanced nicotine delivery equal to that of subjects' usual brands. The latter cigarettes were rated as extremely harsh due to the high nicotine/tar ratio. Trimethaphan significantly attenuated the airway sensations associated with nicotine, and eliminated the difference in smoking satisfaction between the usual brand of cigarette and the other two cigarettes. These findings suggest that nicotinic receptors on peripheral nerve endings in the respiratory tract modulate smoking satisfaction and may be important in the maintenance of cigarette addiction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9972860     DOI: 10.1016/s0091-3057(98)00153-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  31 in total

1.  The airway sensory impact of nicotine contributes to the conditioned reinforcing effects of individual puffs from cigarettes.

Authors:  Nasir H Naqvi; Antoine Bechara
Journal:  Pharmacol Biochem Behav       Date:  2005-08       Impact factor: 3.533

2.  Skin conductance responses are elicited by the airway sensory effects of puffs from cigarettes.

Authors:  Nasir H Naqvi; Antoine Bechara
Journal:  Int J Psychophysiol       Date:  2006-01-05       Impact factor: 2.997

3.  Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).

Authors:  Linda P Dwoskin; B Matthew Joyce; Guangrong Zheng; Nichole M Neugebauer; Vamshi K Manda; Paul Lockman; Roger L Papke; Michael T Bardo; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2007-07-21       Impact factor: 5.858

4.  Reinforcing effects of nicotine and non-nicotine components of cigarette smoke.

Authors:  Jed E Rose; Al Salley; Frederique M Behm; James E Bates; Eric C Westman
Journal:  Psychopharmacology (Berl)       Date:  2010-04-01       Impact factor: 4.530

Review 5.  Nicotine and nonnicotine factors in cigarette addiction.

Authors:  Jed E Rose
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

Review 6.  Measures for assessing subjective effects of potential reduced-exposure products.

Authors:  Karen Hanson; Richard O'Connor; Dorothy Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

7.  Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release.

Authors:  Marharyta Pivavarchyk; Andrew M Smith; Zhenfa Zhang; Dejun Zhou; Xu Wang; Naoki Toyooka; Hiroshi Tsuneki; Toshiyasu Sasaoka; J Michael McIntosh; Peter A Crooks; Linda P Dwoskin
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

Review 8.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 9.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

10.  Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.

Authors:  Zhenfa Zhang; Guangrong Zheng; Marharyta Pivavarchyk; A Gabriela Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2008-09-26       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.